skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In-depth pharmaceutical market coverage

Datamonitor Healthcare | Pharma Intelligence

Discover unmet pharmaceutical needs. Effectively prioritize market opportunities. Deliver optimal returns. Datamonitor Healthcare’s in-depth expert data analysis and robust interactive data tools meet your needs and address your challenges in an ever-changing market.

How it helps

The breadth of coverage ensures you can assess revenue potential and identify competitive threats, market catalysts, and untapped new product development opportunities more holistically than ever before.

How it works

Content created by a global team of award-winning specialist analysts, and an easy-to-use interface that streamlines information gathering make Datamonitor Healthcare the go-to solution for the pharmaceutical and biotechnology industries.  

It offers:

  • Forecasts, built by our analysts, including patient-based, epidemiology, and sales forecasts
  • A myriad of interactive data tools, including treatment, standards of care by country, and patient-based disease forecasts, supported by large-scale primary research with physicians, payers, and key opinion leaders
  • Expert coverage and in-depth analysis of key diseases, companies, drugs and market trends

What's included

Pharma Intelligence: latest

  • Datamonitor Healthcare

    Reimbursement and Payer Management of Immune Checkpoint Inhibitors

    03 Sep 2019

    As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations

    Topic Drug review

  • Datamonitor Healthcare

    NASH Disease Coverage Extract

    16 Aug 2019

    Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.   

    Topic Drug development landscape Diseases

  • Datamonitor Healthcare

    Top 10 Best Selling Drugs of 2018 Fund US and EU Pharma RD

    15 Jul 2019

    Our latest whitepaper lists the top selling drugs last year, who developed them and the strategies behind their success. We drew from three of our top products to create our most recent whitepaper, Datamonitor Health Care, Biomedtracker and Pharmaprojects. You can experience them all for yourself. 

    Topic Drug review Strategy Deal trends

  • Datamonitor Healthcare, Biomedtracker, Pharmapremia

    2019 Q3 Outlook Webinar

    By Hardik Patel 15 Jul 2019

    Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

    Topic immuno-oncology Infectious diseases

  • Datamonitor Healthcare

    Understand Market Access Trends in the US, Europe and Emerging Markets

    03 Jul 2019

    This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

    Topic Drug development landscape Drug approval Drug review

  • Datamonitor Healthcare, Biomedtracker

    Q1 Outlook Webinar: Key Catalysts and their Impact on Pharma Markets

    By Michael ​ Haydock 02 Jul 2019

    Find out which market-moving events and catalysts to watch for during the Q1 Outlook Webinar - Key catalysts and their impact on pharma markets.

    Topic Drug approval Drug development landscape Drug review

  • Datamonitor Healthcare

    Depression Disease Market and Forecast Analysis 2024

    15 Jun 2019

    Informa Pharma Intelligence is marking Depression Awareness Month with a free download of Depression Disease Market and Forecast Analysis 2024. Download your free extract from this vital report and tap into the exclusive data and insights into the depression market available only from the experts at Datamonitor Healthcare, part of the Informa Pharma Intelligence suite of tools.

    Topic Drug development landscape

  • Datamonitor Healthcare

    Better Heart Health Whitepaper

    15 Jun 2019

    In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.

  • Datamonitor Healthcare

    Multiple Myeloma Pricing, Reimbursement, and Access

    13 Jun 2019

    Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

    Topic Cancer Drug development landscape Reimbursement

  • Datamonitor Healthcare

    World AIDS Day 2018 GlaxoSmithKline report

    11 Jun 2019

    PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    Topic Diseases Drug development landscape Drug review

  • Datamonitor Healthcare

    Global Market Access Webinar

    By Louisa Joseph 13 May 2019

    Join subject-matter experts from Datamonitor Healthcare as they use data and their industry experience to examine the challenges and opportunities brought about by recent global trends in market access. Learn how to navigate this complex terrain, as increasingly restrictive pricing and reimbursement policies are having an adverse effect on sales of launched and pipeline products across many global markets.

    Topic Reimbursement

  • Datamonitor Healthcare

    HIV Market Growth webinar

    By Michael ​ Haydock 15 Apr 2019

    Mr. Haydock & Mr. Haas used the exclusive information within Datamonitor Healthcare and Biomedtracker to present a view of the market for HIV drugs. Informa Pharma Intelligence forecasts HIV sales revenues to increase in the US and five major EU markets to a peak of $22.7bn in 2024 before generic erosion triggers a market decline.

  • Datamonitor Healthcare

    Lysosomal Storage Disorders (LSDs): Epidemiology & Treatment Overview

    By Niharika Dandamudi 15 Apr 2019

    Lysosomal storage diseases (LSDs) are a rare distinct group of disorders with complex diagnosis and limited epidemiology data, such as Pompe disease. In recognition of International Pompe Day, marked on April 15, we created the below infographic to provide some insight into epidemiology and present an overview of current treatment options.

    Topic Diseases

  • Datamonitor Healthcare

    Pharma Diabetes Market Intelligence

    10 Apr 2019

    These reports includes 20-year forecasts of prevalent type 1 and type 2 diabetes cases segmented by age and gender, and drug-treated diabetes, segmented by treatment type.

    Topic Diabetes

  • Datamonitor Healthcare

    Gene Therapy: A Paradigm Shift in Medicine

    By Amanda Micklus 10 Apr 2019

    The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

    Topic Cell and gene therapy

Meet the team


Rachel Meighan-Mantha

Analyst, Principal Analyst
Rachel Meighan-Mantha

Rachel specializes in

  • Oncology
  • Clinical Trials

+22 year(s) experience


Amanda Micklus

Analyst, Principal Analyst


Amanda Micklus

Amanda specializes in

  • Oncology
  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience


Michael Hay

Management, Head of Intelligence Products
Michael Hay

Michael specializes in

  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Keep up to date

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: